Susquehanna Fundamental Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Susquehanna Fundamental Investments’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,184	Closed	-$224K	–	603
2025 Q4	$224K	Hold	1,184	–	–	0.01%	505
2025 Q3	$210K	Buy	+1,184	New	+$176K	0.01%	512
2025 Q2	–	Sell	-11,167	Closed	-$1.17M	–	884
2025 Q1	$1.17M	Buy	+11,167	New	+$1.26M	0.02%	655
2023 Q2	–	Sell	-9,470	Closed	-$697K	–	779
2023 Q1	$697K	Hold	9,470	–	–	0.02%	606
2022 Q4	$633K	Sell	9,470 -13,405	-59%	-$872K	0.01%	791
2022 Q3	$1.23M	Buy	+22,875	New	+$1.34M	0.02%	736
2022 Q1	$540K	Buy	+7,694	New	+$558K	0.01%	1045

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Susquehanna Fundamental Investments's LGND Position: Q1 2026 in Review

Susquehanna Fundamental Investments sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 1,184 shares — an estimated $224K sold.

Susquehanna Fundamental Investments first reported a position in LGND in Q1 2022 and held it in 7 quarters. The position peaked at $1.23M in Q3 2022. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

Susquehanna Fundamental Investments reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Susquehanna Fundamental Investments sold 1,184 Ligand Pharmaceuticals shares in Q1 2026, an estimated $224K.
Susquehanna Fundamental Investments first reported a position in Ligand Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Susquehanna Fundamental Investments's Ligand Pharmaceuticals position peaked at $1.23M in Q3 2022.
357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2026, filed 15 May 2026.